AGIOS PHARMACEUTICALS, INC. Increase Decrease In Operating Lease Liability
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Increase Decrease In Operating Lease Liability of -$9.04 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-07-30
- AGIOS PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$4.57M.
- AGIOS PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$4.46M.
- AGIOS PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$4.31M.
- AGIOS PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$4.25M.
- AGIOS PHARMACEUTICALS, INC. increase decrease in operating lease liability for fiscal 2025 was -$16.78M.
- AGIOS PHARMACEUTICALS, INC. increase decrease in operating lease liability for fiscal 2024 was -$15.01M.
- AGIOS PHARMACEUTICALS, INC. increase decrease in operating lease liability for fiscal 2023 was -$13.66M.
- AGIOS PHARMACEUTICALS, INC. increase decrease in operating lease liability for fiscal 2022 was -$10.83M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$9.04M 10-Q · filed 2026-07-30 | -$13.34M derived: sum of 3 quarters · filed 2026-07-30 | -$17.59M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | -$4.46M 10-Q · filed 2026-04-29 | -$8.77M derived: sum of 2 quarters · filed 2026-04-29 | -$13.02M derived: sum of 3 quarters · filed 2026-04-29 | -$17.20M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | -$4.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$8.55M derived: sum of 2 quarters · filed 2026-02-12 | -$12.73M derived: sum of 3 quarters · filed 2026-07-30 | -$16.78M 10-K · filed 2026-02-12 |
| 2025-09-30 | -$4.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$8.43M derived: sum of 2 quarters · filed 2026-07-30 | -$12.47M 10-Q · filed 2025-10-30 | -$16.32M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | -$4.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$8.23M 10-Q · filed 2026-07-30 | -$12.07M derived: sum of 3 quarters · filed 2026-07-30 | -$15.86M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$4.05M 10-Q · filed 2026-04-29 | -$7.89M derived: sum of 2 quarters · filed 2026-04-29 | -$11.68M derived: sum of 3 quarters · filed 2026-04-29 | -$15.41M derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | -$3.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$7.63M derived: sum of 2 quarters · filed 2026-02-12 | -$11.36M derived: sum of 3 quarters · filed 2026-02-12 | -$15.01M 10-K · filed 2026-02-12 |
| 2024-09-30 | -$3.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$7.51M derived: sum of 2 quarters · filed 2025-10-30 | -$11.16M 10-Q · filed 2025-10-30 | -$14.66M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | -$3.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | -$7.38M 10-Q · filed 2025-07-31 | -$10.88M derived: sum of 3 quarters · filed 2026-02-12 | -$14.33M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | -$3.65M 10-Q · filed 2025-05-01 | -$7.15M derived: sum of 2 quarters · filed 2026-02-12 | -$10.60M derived: sum of 3 quarters · filed 2026-02-12 | -$13.99M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | -$3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$6.95M derived: sum of 2 quarters · filed 2026-02-12 | -$10.34M derived: sum of 3 quarters · filed 2026-02-12 | -$13.66M 10-K · filed 2026-02-12 |
| 2023-09-30 | -$3.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$6.84M derived: sum of 2 quarters · filed 2024-10-31 | -$10.16M 10-Q · filed 2024-10-31 | -$13.34M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-06-30 | -$3.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$6.71M 10-Q · filed 2024-08-01 | -$9.89M derived: sum of 3 quarters · filed 2025-02-13 | -$11.99M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-03-31 | -$3.32M 10-Q · filed 2024-05-02 | -$6.50M derived: sum of 2 quarters · filed 2025-02-13 | -$8.60M derived: sum of 3 quarters · filed 2025-02-13 | -$11.74M derived: sum of 4 quarters · filed 2025-02-13 |
| 2022-12-31 | -$3.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | -$5.28M derived: sum of 2 quarters · filed 2025-02-13 | -$8.42M derived: sum of 3 quarters · filed 2025-02-13 | -$10.83M 10-K · filed 2025-02-13 |
| 2022-09-30 | -$2.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$5.24M derived: sum of 2 quarters · filed 2023-11-02 | -$7.65M 10-Q · filed 2023-11-02 | -$9.86M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | -$3.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$5.55M 10-Q · filed 2023-08-03 | -$7.76M derived: sum of 3 quarters · filed 2024-02-15 | -$9.45M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | -$2.40M 10-Q · filed 2023-05-04 | -$4.62M derived: sum of 2 quarters · filed 2024-02-15 | -$6.30M derived: sum of 3 quarters · filed 2024-02-15 | -$8.43M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | -$2.21M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$3.90M derived: sum of 2 quarters · filed 2024-02-15 | -$6.02M derived: sum of 3 quarters · filed 2024-02-15 | -$7.53M 10-K · filed 2024-02-15 |
| 2021-09-30 | -$1.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$3.81M derived: sum of 2 quarters · filed 2022-11-03 | -$5.32M 10-Q · filed 2022-11-03 | -$7.33M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | -$2.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$3.63M 10-Q · filed 2022-08-04 | -$5.65M derived: sum of 3 quarters · filed 2023-02-23 | -$7.61M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | -$1.50M 10-Q · filed 2022-05-05 | -$3.52M derived: sum of 2 quarters · filed 2023-02-23 | -$5.48M derived: sum of 3 quarters · filed 2023-02-23 | |
| 2020-12-31 | -$2.02M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$3.98M derived: sum of 2 quarters · filed 2023-02-23 | -$8.13M 10-K · filed 2023-02-23 | |
| 2020-09-30 | -$1.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$6.11M 10-Q · filed 2021-11-03 | ||
| 2020-06-30 | -$4.15M 10-Q · filed 2021-07-29 | |||
| 2019-12-31 | -$6.86M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |